RT Journal Article
SR Electronic
T1 Pan-cancer proteogenomic landscape of whole-genome doubling reveals putative therapeutic targets in various cancer types
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.16.24305805
DO 10.1101/2024.04.16.24305805
A1 Chang, Eunhyong
A1 Hwang, Hee Sang
A1 Song, Kyu Jin
A1 Kim, Kwoneel
A1 Kim, Min-Sik
A1 Jang, Se Jin
A1 Kim, Kwang Pyo
A1 You, Sungyong
A1 An, Joon-Yong
YR 2024
UL http://medrxiv.org/content/early/2024/04/18/2024.04.16.24305805.abstract
AB Background Whole-genome doubling (WGD) is prevalent in cancer and drives tumor development and chromosomal instability. Driver mutations in mitotic cell cycle genes and cell cycle upregulation have been reported as the major molecular underpinnings of WGD tumors. However, the underlying genomic signatures and regulatory networks involved in gene transcription and kinase phosphorylation remain unclear. Here, we aimed to comprehensively decipher the molecular landscape underlying WGD tumors.Methods We performed a pan-cancer proteogenomic analysis and compared 10 cancer types by integrating genomic, transcriptomic, proteomic, and phosphoproteomic datasets from the Clinical Proteomic Tumor Analysis Consortium (CPTAC). We also integrated the cancer dependency data of each cancer cell line and the survival properties of each cancer patient to propose promising therapeutic targets for patients with WGD.Results Our study delineated distinct copy number signatures characterizing WGD-positive tumors into three major groups: highly unstable genome, focal instability, and tetraploidy. Furthermore, the analysis revealed the heterogeneous mechanisms underlying WGD across cancer types with specific structural variation patterns. Upregulation of the cell cycle and downregulation of the immune response were found to be specific to certain WGD tumor types. Transcription factors (TFs) and kinases exhibit cancer-specific activities, emphasizing the need for tailored therapeutic approaches.Conclusion This study introduces an integrative approach to identify potential TF targets for drug development, highlighting BPTF as a promising candidate for the treatment of head and neck squamous cell carcinoma. Additionally, drug repurposing strategies have been proposed, suggesting potential drugs for the treatment of WGD-associated cancers. Our findings offer insights into the heterogeneity of WGD and have implications for precision medicine approaches for cancer treatment.Competing Interest StatementKwang Pyo Kim is the CEO of NioBiopharmaceuticals, Inc. Se Jin Jang is the chief executive officer of Oncoclew, Co., Ltd. All other authors report no conflict of interest.Funding StatementThis study was funded by the National Research Foundation of Korea (NRF) grant funded by the Korea government (NRF-2019M3E5D3073568 to Joon-Yong An) and by the Ministry of Science and ICT (NRF-2022R1A2C2013377 to Min-Sik Kim), the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (RS-2023-00304839 to Kwoneel Kim), and Korea University to Joon-Yong An. Eunhyong Chang received a scholarship from the Kwanjeong Educational Foundation and the Brain Korea (BK21) FOUR education program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The source data are openly available before the initiation of this study. Genome and transcriptome data were downloaded from the GDC data portal (https://portal.gdc.cancer.gov). Global proteomic and phosphoproteomic data were downloaded from LinkedOmics (https://www.linkedomics.org/).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesPublic CPTAC datasets are available within 11 publications 9–18. Genome and transcriptome data were downloaded from the GDC data portal (https://portal.gdc.cancer.gov). Global proteomic and phosphoproteomic data were downloaded from LinkedOmics (https://www.linkedomics.org/). All data generated during this study are included in Supporting Information.WGDWhole-genome doublingCINChromosomal instabilityBRCABreast cancerCCRCCClear cell renal cell carcinomaCOADColon adenocarcinomaGBMGlioblastomaHGSCHigh-grade serous carcinomaHNSCCHead and neck squamous cell carcinomaLUADLung adenocarcinomaLSCCLung squamous cell carcinomaPDACPancreatic ductal adenocarcinomaUCECUterine corpus endometrial carcinomaLOHLoss-of-heterozygosityTMBTumor mutational burdenCNCopy numberTFTranscription factor